Cisplatin is an antineoplastic agent used to treat various tumors. In mammals, it can cause nephrotoxicity, tissue damage, and inflammation. The release of inflammatory mediators leads to the recruitment and infiltration of immune cells, particularly neutrophils, at the site of inflammation. Cisplatin is often used as an inducer of acute kidney injury (AKI) in experimental models, including zebrafish (Danio rerio), due to its accumulation in kidney cells. Current protocols in larval zebrafish focus on studying its effect as an AKI inducer but ignore other systematic outcomes. In this study, cisplatin was added directly to the embryonic medium to assess its toxicity and impact on systemic inflammation using locomotor activity analysis, qPCR, microscopy, and flow cytometry. Our data showed that larvae exposed to cisplatin at 7 days post-fertilization (dpf) displayed dose-dependent mortality and morphological changes, leading to a decrease in locomotion speed at 9 dpf. The expression of pro-inflammatory cytokines such as interleukin (il)-12, il6, and il8 increased after 48 h of cisplatin exposure. Furthermore, while a decrease in the number of neutrophils was observed in the glomerular region of the pronephros, there was an increase in neutrophils throughout the entire animal after 48 h of cisplatin exposure. We demonstrate that cisplatin can have systemic effects in zebrafish larvae, including morphological and locomotory defects, increased inflammatory cytokines, and migration of neutrophils from the hematopoietic niche to other parts of the body. Therefore, this protocol can be used to induce systemic inflammation in zebrafish larvae for studying new therapies or mechanisms of action involving neutrophils.
Colorectal cancer (CRC) is the fourth most common and the third mostly deadly cancer globally. Even with alternative therapies, some patients do not respond to treatment. Identifying modulations in the tumor microenvironment (TME) of CRC is a significant challenge due to the complex and dynamic nature of the TME. The intestinal epithelium comprises different types of secretory lineage cells, including goblet, tuft, Paneth, and enteroendocrine cells (EECs). Yet the relevance of each subtype of secretory intestinal epithelial cell (IEC) within the TME is still debated. This study investigated the involvement of IECs in CRC development through an integrative bioinformatics analysis. We used publicly available datasets from the National Center for Biotechnology Information, the Cancer Genome Atlas Program, and the National Cancer Institute’s Proteomics Tumor Analysis Consortium, encompassing both human and mouse CRC samples. Our findings reveal a CRC microenvironment characterized by elevated expression levels of genes associated with WNT pathway activity. Remarkably, there was increased expression of Paneth cell-associated markers and transcription factors, such as WISP1, LYZ, SOX9, and DEFA1. Conversely, EEC-specific gene markers, such as GCG (encoding glucagon-like peptide-1) and CHGA exhibited significant downregulation in CRC tissue compared with healthy tissue, partially due to Paneth cell activity. Gene ontology analysis showed species-conserved downregulation in hormone/peptide secretion-related pathways in both mouse and human CRC. Of note, lower levels of GCG and CHGA correlated with reduced overall survival and demonstrated a correlation with the cell cycle, apoptosis, and proliferation. These results suggest that the disruption of enteroendocrine cell signaling is a hallmark of CRC development and may hold prognostic and therapeutic value in treating CRC patients.
Colorectal cancer (CRC) is the fourth and the third most common and deadlycancer, respectively, worldwide. Even with alternative therapies, some patients do notrespond to treatment. Identifying modulations in the tumor microenvironment (TME) ofCRC is indeed a challenge due to the complex and dynamic nature of the TME. Theintestinal epithelial cells (IECs) are composed by different types of secretory-lineagecells, such as goblet, tuft, paneth and enteroendocrine cells (EECs). Yet, the relevanceof each subtype of secretory IEC in the tumor microenvironment is still a matter of debate.This study investigated the involvement of IECs in CRC through an integrativebioinformatics analysis using publicly available datasets from National Center forBiotechnology Information (NCBI) and The Cancer Genome Atlas Program (TCGA),encompassing both human and mouse CRC samples. Our findings reveal a CRC TMEfeatured by elevated expression levels of genes associated with WNT pathway activity.Remarkably, there was an increased expression of Paneth cell-associated markers andtranscription factors, such as WISP1, LYZ, SOX9, and DEFA1 while enteroendocrinecells-specific gene markers, such as GCG (encoding Glucagon like Peptide-1) andCHGA exhibited a significant downregulation in CRC tissue compared with health tissue.Gene ontology (GO) analysis showed a species-conserved downregulation inhormone/peptide secretion-related pathways of CRC in mouse and human. Of note,lower levels of GCG and CHGA correlated with reduced overall survival andchemotherapy-unresponsive patients. These results suggest that disruption of EECsignaling is a hallmark of CRC development and may hold prognostic and therapeuticvalue for treating CRC patients.
Regulatory T (Treg) cells expressing RORgamma-t accumulate in the intestinal mucosa, yet the signals that determine whether they remain suppressive or acquire inflammatory features are incompletely defined. We first reanalyzed human ileal single-cell data and identified Crohn's disease-enriched FOXP3+ states in which RORC, HIF1A, hypoxia-responsive, inflammatory, and metabolic programs converged. We then deleted Hif1a in RORgamma-t-expressing cells and tested acute DSS colitis, T cell transfer colitis, and azoxymethane/DSS-induced colitis-associated colorectal cancer (CAC). Hif1a-deficient mice were protected in all three settings. In lymphopenic recipients given the same pathogenic naive T cells, changing only the genotype of the cotransferred Treg population enhanced protection, linking the phenotype to regulatory-cell function in vivo. Reanalysis of mouse colonic Treg single-cell ATAC-seq nominated suppressive and mitochondrial programs for cell-intrinsic testing under conditions of low HIF-1alpha expression. Hif1a-deficient RORgamma-t Treg cells produced more IL-10 and less IL-17A and IFN-gamma, limited responder-cell proliferation, contained fewer dysfunctional mitochondria with high mitochondrial reactive oxygen species levels, favored fusion-associated transcription, and displayed greater basal and maximal oxygen consumption and reserve capacity. During CAC, HIF-1alpha loss blunted inflammatory RORgamma-t Treg accumulation and reduced tumor burden. Human trajectory and gene regulatory network analyses further predicted that HIF1A perturbation would oppose selected disease-associated branches. Together, these findings identify HIF-1alpha as a context-dependent checkpoint that connects hypoxia-responsive transcription to mitochondrial fitness and inflammatory plasticity in intestinal RORgamma-t Treg cells.
Background: RORγt + regulatory T cells (Treg) play a crucial role in immune regulation, particularly in the gut. However, most current knowledge about this subset derives from in vivo studies, as in vitro investigation has been limited by the lack of protocols capable of preserving their phenotype. Methods: Here, we developed and optimized an in vitro differentiation protocol to efficiently generate RORγt + Treg cells. The protocol was evaluated based on the frequency of RORγt + Treg cells generated, their suppressive function compared to conventional induced Treg (iTreg), and their metabolic profile. Results: The optimized protocol increased the frequency of RORγt + Treg cells in vitro by up to 70%, providing a robust system for their study. Functionally, in vitro –differentiated RORγt + Treg cells displayed enhanced immunosuppressive activity compared to conventional iTreg, effectively inhibiting effector CD4⁺ T cell proliferation. Metabolic analyses further revealed a reliance on oxidative phosphorylation (OXPHOS) in this subset. Conclusion: This protocol enables the efficient in vitro generation of RORγt + Treg cells, facilitating functional and metabolic studies of this population and opening new avenues for potential therapeutic applications in immune-mediated diseases.